Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465179 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00465179: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00465179 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00465179, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn the effectiveness of Sutent® (sunitinib malate, SU011248) in the treatment of patients with non-clear cell renal cell cancer. The safety of sunitinib malate will also be studied.
Interventions
- DRUG Sunitinib Malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2007-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465179
The ClinicalTrials.gov registry entry for NCT00465179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sunitinib Malate is the first listed.
NCT00465179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465179 about?
NCT00465179 is a clinical study titled "Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer". The goal of this clinical research study is to learn the effectiveness of Sutent® (sunitinib malate, SU011248) in the treatment of patients with non-clear cell renal cell cancer. The safety of sunitinib malate will also be studied.
What is the current status of trial NCT00465179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2007-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00465179?
The interventions under investigation include: Sunitinib Malate (DRUG).
Who is sponsoring clinical trial NCT00465179?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.